Zoledronic acid
Zoledronic acid, also known as zoledronate and sold under the brand name Zometa by Novartis among others, is a medication used to treat a number of bone diseases. These include osteoporosis, high blood calcium due to cancer, bone breakdown due to cancer, Paget's disease of bone and Duchenne muscular dystrophy (DMD). It is given by injection into a vein.
Clinical data | |
---|---|
Trade names | Reclast, Zometa, others |
Other names | zoledronate |
AHFS/Drugs.com | Monograph |
MedlinePlus | a605023 |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous |
Drug class | Bisphosphonate |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 22% |
Metabolism | Nil |
Elimination half-life | 146 hours |
Excretion | Kidney (partial) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C5H10N2O7P2 |
Molar mass | 272.090 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Common side effects include fever, joint pain, high blood pressure, diarrhea, and feeling tired. Serious side effects may include kidney problems, low blood calcium, and osteonecrosis of the jaw. Use during pregnancy may result in harm to the baby. It is in the bisphosphonate family of medications. It works by blocking the activity of osteoclast cells and thus decreases the breakdown of bone.
Zoledronic acid was patented in 1986 and approved for medical use in the United States in 2001. It is on the World Health Organization's List of Essential Medicines.